{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:16:13Z","timestamp":1784614573406,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.cct.2020.106094","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T22:24:13Z","timestamp":1596147853000},"page":"106094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis"],"prefix":"10.1016","volume":"96","author":[{"given":"Srinivasan","family":"Dasarathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mack C.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"McClain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyongyi","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Radaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2020.106094_bb0005","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/acer.12887","article-title":"Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States","volume":"39","author":"Guirguis","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.cct.2020.106094_bb0010","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2020.106094_bb0015","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jhep.2015.03.006","article-title":"Trends in the management and burden of alcoholic liver disease","volume":"62","author":"Mathurin","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cct.2020.106094_bb0020","first-page":"307","article-title":"Practice guideline committee of the american association for the study of liver D, practice parameters Committee of the American College of G. alcoholic liver disease","volume":"51","author":"O\u2019Shea","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2020.106094_bb0025","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1056\/NEJMra0805786","article-title":"Alcoholic hepatitis","volume":"360","author":"Lucey","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.106094_bb0030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MCG.0000000000000161","article-title":"Evolving alcoholic hepatitis treatment C. trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States","volume":"49","author":"Jinjuvadia","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.cct.2020.106094_bb0035","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/MCG.0b013e3181fdef1d","article-title":"Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States","volume":"45","author":"Liangpunsakul","year":"2011","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.cct.2020.106094_bb0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.alcohol.2018.02.003","article-title":"Mortality and costs associated with alcoholic hepatitis: a claims analysis of a commercially insured population","volume":"71","author":"Thompson","year":"2018","journal-title":"Alcohol"},{"key":"10.1016\/j.cct.2020.106094_bb0045","author":"Chen CY, Y-H","year":"2013"},{"key":"10.1016\/j.cct.2020.106094_bb0050","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/MPA.0b013e3180cac24b","article-title":"Direct medical costs of acute pancreatitis hospitalizations in the United States","volume":"35","author":"Fagenholz","year":"2007","journal-title":"Pancreas"},{"key":"10.1016\/j.cct.2020.106094_bb0055","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2010.07.016","article-title":"Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study","volume":"54","author":"Sandahl","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cct.2020.106094_bb0060","first-page":"210","article-title":"Prognostic factors in alcoholic liver disease. VA cooperative study group","volume":"86","author":"Chedid","year":"1991","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cct.2020.106094_bb0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ajg.2017.469","article-title":"ACG clinical guideline: alcoholic liver disease","volume":"113","author":"Singal","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cct.2020.106094_bb0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2012.04.004","article-title":"EASL clinical practical guidelines: management of alcoholic liver disease","volume":"57","author":"European Association for the Study of L","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cct.2020.106094_bb0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cgh.2016.08.047","article-title":"Medical Management of Severe Alcoholic Hepatitis: expert review from the clinical practice updates committee of the AGA Institute","volume":"15","author":"Mitchell","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cct.2020.106094_bb0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2020.106094_bb0085","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.106094_bb0090","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-0037-1608788","article-title":"Clinical trial design for alcoholic hepatitis","volume":"37","author":"Szabo","year":"2017","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.cct.2020.106094_bb0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","article-title":"Inflammatory pathways in alcoholic steatohepatitis","volume":"70","author":"Gao","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cct.2020.106094_bb0100","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3748\/wjg.v16.i11.1321","article-title":"Alcoholic liver disease and the gut-liver axis","volume":"16","author":"Szabo","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cct.2020.106094_bb0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4254\/wjh.v9.i12.567","article-title":"Emerging concepts in alcoholic hepatitis","volume":"9","author":"Fung","year":"2017","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.cct.2020.106094_bb0110","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3748\/wjg.15.3194","article-title":"Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome?","volume":"15","author":"Assimakopoulos","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cct.2020.106094_bb0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.livres.2017.12.004","article-title":"Targeting the gut barrier for the treatment of alcoholic liver disease","volume":"1","author":"Zhou","year":"2017","journal-title":"Liver Res"},{"key":"10.1016\/j.cct.2020.106094_bb0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/1574887111666160810101202","article-title":"Epidemiology and natural history of alcoholic liver disease","volume":"11","author":"Masarone","year":"2016","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.cct.2020.106094_bb0125","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2020.106094_bb0130","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0016-5085(99)70354-9","article-title":"Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice","volume":"117","author":"Yin","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2020.106094_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1053\/jhep.2001.25350","article-title":"Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice","volume":"34","author":"Uesugi","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2020.106094_bb0140","doi-asserted-by":"crossref","first-page":"G516","DOI":"10.1152\/ajpgi.00537.2010","article-title":"Innate immunity in alcoholic liver disease","volume":"300","author":"Gao","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cct.2020.106094_bb0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1189\/jlb.3AB1214-590R","article-title":"Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease","volume":"98","author":"Petrasek","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cct.2020.106094_bb0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","article-title":"Inflammasome activation and function in liver disease","volume":"12","author":"Szabo","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cct.2020.106094_bb0155","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cct.2020.106094_bb0160","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cct.2020.106094_bb0165","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cct.2020.106094_bb0170","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for rheumatoid arthritis: a systematic review","volume":"36","author":"Mertens","year":"2009","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cct.2020.106094_bb0175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cct.2020.106094_bb0180","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cct.2020.106094_bb0185","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0162-3109(00)00249-6","article-title":"Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages","volume":"49","author":"Marcinkiewicz","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.cct.2020.106094_bb0190","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/pr.2017.6","article-title":"Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns","volume":"81","author":"Speer","year":"2017","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.cct.2020.106094_bb0195","article-title":"Pentoxifylline modulates intestinal tight junction signaling after burn injury: effects on myosin light chain kinase","volume":"66","author":"Costantini","year":"2009","journal-title":"J. Trauma"},{"key":"10.1016\/j.cct.2020.106094_bb0200","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MEG.0b013e3283435d76","article-title":"Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo","volume":"23","author":"Tyagi","year":"2011","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cct.2020.106094_bb0205","first-page":"1003","article-title":"Protective effect of pentoxyfilline in renal toxicity after methotrexate administration","volume":"15","author":"Asvadi","year":"2011","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.cct.2020.106094_bb0210","doi-asserted-by":"crossref","first-page":"969","DOI":"10.5301\/jn.5000077","article-title":"Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial","volume":"25","author":"Goicoechea","year":"2012","journal-title":"J. Nephrol."},{"key":"10.1016\/j.cct.2020.106094_bb0215","doi-asserted-by":"crossref","first-page":"41930","DOI":"10.1074\/jbc.M107181200","article-title":"Stabilization of tumor necrosis factor alpha mRNA by chronic ethanol: role of A + U-rich elements and p38 mitogen-activated protein kinase signaling pathway","volume":"276","author":"Kishore","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cct.2020.106094_bb0220","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s000110050475","article-title":"Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis","volume":"48","author":"Taguchi","year":"1999","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.cct.2020.106094_bb0225","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3748\/wjg.15.1613","article-title":"Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial","volume":"15","author":"De","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cct.2020.106094_bb0230","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jhep.2007.10.010","article-title":"Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids","volume":"48","author":"Louvet","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cct.2020.106094_bb0235","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2020.106094_bb0240","first-page":"144","article-title":"Zinc and its importance for human health: an integrative review","volume":"18","author":"Roohani","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.cct.2020.106094_bb0245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0884533611433534","article-title":"Zinc and liver disease","volume":"27","author":"Mohammad","year":"2012","journal-title":"Nutr. Clin. Pract."},{"key":"10.1016\/j.cct.2020.106094_bb0250","first-page":"185","article-title":"Functional consequences of zinc deficiency","volume":"9","author":"McClain","year":"1985","journal-title":"Prog. Food Nutr. Sci."},{"key":"10.1016\/j.cct.2020.106094_bb0255","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/hep.23090","article-title":"Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha","volume":"50","author":"Kang","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2020.106094_bb0260","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0002-9440(10)62478-9","article-title":"Zinc supplementation prevents alcoholic liver injury in mice through attenuation of oxidative stress","volume":"166","author":"Zhou","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cct.2020.106094_bb0265","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2307\/2531910","article-title":"Sample sizes based on the log-rank statistic in complex clinical trials","volume":"44","author":"Lakatos","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2020.106094_bb0270","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1740774519868479","article-title":"Noninferiority trials with nonadherence to the assigned randomized treatment","volume":"16","author":"Korn","year":"2019","journal-title":"Clin. Trials"},{"key":"10.1016\/j.cct.2020.106094_bb0275","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2307\/2531201","article-title":"Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification","volume":"42","author":"Lachin","year":"1986","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2020.106094_bb0280","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2020.106094_bb0285","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/gut.2010.224097","article-title":"Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data","volume":"60","author":"Mathurin","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.cct.2020.106094_bb0290","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2020.106094_bb0295","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM198412063112302","article-title":"Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone","volume":"311","author":"Mendenhall","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.106094_bb0300","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/acer.13515","article-title":"Challenges in patient Enrollment and retention in clinical studies for alcoholic hepatitis: experience of the TREAT consortium","volume":"41","author":"Comerford","year":"2017","journal-title":"Alcohol. Clin. Exp. Res."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420301725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420301725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:50:23Z","timestamp":1761555023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714420301725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":60,"alternative-id":["S1551714420301725"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2020.106094","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2020.106094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106094"}}